ReviewClinical and experimental medicine2022
COVID-19-associated opportunistic infections: a snapshot on the current reports.
Review in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Viral reactivations and co-infections in COVID-19 patients: a systematic review.BMC infectious diseases · 2023Pooled it
- Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination.The Yale journal of biology and medicine · 2022Pooled it
- Pooled it
- Impact of Prior Exposure to Anisakis simplex Antigens on Immune Response During SARS-CoV-2 Vaccination.Parasite immunology · 2026Article
- COVID-19 Is Airborne AIDS: Provocative Oversimplification, Emerging Science, or Something in Between?AJPM focus · 2026Review
- Fungal infections of the lung during and after the COVID-19 pandemic: Retrospective observational comparison.Medicine · 2026Observational
- The Influence of COVID-19 on the Composition and Drug Resistance of Pleural Effusion in Shandong Province.MicrobiologyOpen · 2026Article
- Active surveillance of cytomegalovirus and pulmonary aspergillosis in critically ill patients with COVID-19: risk assessment of high-dose steroids.BMC infectious diseases · 2026Article
- Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report.Journal of medical case reports · 2026Article
- A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated MucormycosisEndocrine, metabolic & immune disorders drug targets · 2026Article
- Comparative study of COVID-19 patients admitted during the first and second waves in a tertiary care hospital in Eastern India: a retrospective observational study.Sudanese journal of paediatrics · 2026Article
- Post-coronavirus disease bilateral endogenous fungal endophthalmitis with full visual acuity recovery: a case report.Journal of medical case reports · 2025Article
- Promising Prodiginins Biological Activities.Chemistry & biodiversity · 2025Review
- Invasive pulmonary cryptococcosis mimicking metastatic lung cancer: A case report and review of literature.World journal of clinical cases · 2025Article
- Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Incidence and Temporal Dynamics of Combined Infections in SARS-CoV-2-Infected Patients With Risk Factors for Severe Complications.Journal of Korean medical science · 2025Article
- Enhanced biocidal efficacy of alcohol based disinfectants with salt additives.Scientific reports · 2025Article
- Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview.Infectious disorders drug targets · 2025Review
- Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.